Taha Qazi, MD: Finding Upadacitinib's Role in Crohn's Disease
Qazi reviews the selective JAK1 inhibitor's benefit for patients who previously failed TNF inhibitor regimen.
Read More
People Cured of Hepatitis C Still Face Significant Mortality Risk
A multinational study shows people who achieve sustained virologic response still face a 3-fold greater risk or more of mortality due to liver disease or drug-related issues.
Hepatitis B Elimination Goal May Be Unrealistic for 2030
Global estimate prevalence data suggest the virus affects more than 3% of the population, with available treatment and vaccination strategies used too infrequently.
Lipid-Lowering Drug Target Linked to Increased IBD Risk
A protein targeted by some marketed lipid-lowering agents may increase risk of developing irritable bowel disease.
Cigarette Pack-Years Linked to Recurrent Colorectal Neoplasia in IBD Patients
The first known dose-effect relationship study between colorectal neoplasia and smoking in patients with IBD strengthens the importance of achieving cessation.
Apellis Reviewing Retinal Vasculitis Cases in Pegcetacoplan-Treated GA Patients
Reports of a half-dozen confirmed cases of the rare vision-threatening condition has spurred conversation around the first-in-class geographic atrophy drug.
Alcohol-Related Deaths Increasing Among US Women
New cross-sectional data show the sex gap in alcohol-related mortality has been narrowing since 1999, as women have become more susceptible to alcohol use and related diseases.
Patient Age, Antibiotics, and FMT Donor Influence Recurrent C. Difficile Resolution
New cohort analysis data provide more context into what factors influence the benefit of FMT in patients with recurrent CDI.
Patients with Crohn's Disease Report Low Calcium, Magnesium Intake
A study from China suggests calcium and magnesium malnutrition is associated with Crohn's disease inflammation and activity.
Julia Moore Vogel, PhD, MBA: How Do We Define Long Covid Patients?
Vogel reviews the struggles behind adequately diagnosing long Covid and quantifying its impact of disease at this time of clinical research.
US Maternal Hepatitis C Infections Increased 16-Fold Since 1998
Skyrocketing rates of HCV have aligned with the opioid epidemic—and evidence the need for universal pregnancy screenings.
Africa Challenged by Hepatitis B Mother-to-Child Transmissions
Though many countries established guidelines and strategies to eliminate the virus by 2030, the region is still behind on newborn virus management.
Julia Moore Vogel, PhD, MBA: Long Covid Care Lacks Urgency
Lungcast's July episode guest discusses how long Covid therapy development is still about 5 years away from the market.
High Parathyroid Hormone Levels Linked to NAFLD
A meta-analysis suggest the correlation between PTH and non-alcoholic fatty liver disease is significant enough for it to be biomarker for disease.
Alcohol-Associated Hepatitis Rapidly Increasing in the US
A retrospective analysis shows the highly deadly condition has increased 7-fold among US women in the last 2 decades.
Chronic Liver Disease Linked to Significant Risk of COVID-19 Pneumonia, Death
International data show conditions including cirrhosis and alcohol-associated liver disease significantly drive the likelihood of critical illness and death in COVID-19 patients.
Long COVID Research and Breakthroughs with Julia Moore Vogel, PhD, MBA
In the latest Lungcast, a nationally-leading researcher and long COVID patient discusses what's known and unknown about the chronic viral syndrome.
Amid Social and Political Strife, Medical Schools Seek a Modern Approach
Over 3 years, global health threats and national headlines have spurred medical schools to better address social and community-based determinants of health. What comes next?
CDC Experts Recommend Single-Visit Hepatitis C Antibody, RNA Testing
An update to guidances prioritizes practices that complete RNA testing on all HCV antibody reactive samples in one step, for the sake of complete test rates.
Virginia Health Clinic Provides Blueprint for Treating Local HCV Patients with Substance History
A Lynchburg-based clinic was able to cure hepatitis C in all follow-through patients with substance abuse who underwent a comprehensive care plan over 8 weeks.
Needle Stick Injuries Common Among Health Care Workers Not Fully Vaccinated for HBV
A study from Nepal showed a majority of teaching hospital health providers were accidentally exposed to needles. The group additionally had limited knowledge of their HBV vaccination status.
Preference for an Alternative to Colonoscopies Growing in the US
New data from the CONFIRM trial show the noninvasive FIT testing method is increasing in preference over colonoscopy by about 20% annually.
Type 2 Diabetes Increases Liver Decompensation, Cancer Risk in NAFLD Patients
A meta-analysis shows patients with both NAFLD and type 2 diabetes are at significantly greater risk of hepatic decompensation and HCC over a 5-year span.
HCV Antivirals May Improve Hepatocellular Carcinoma Survival Rates
Direct-acting antivirals or interferon may improve the rate of overall or recurrence-free survival for patients with liver cancer.
Fecal Incontinence is Highly Associated with IBS or Constipation
A cross-sectional analysis from China suggests approximately 1 in 10 individuals suffer from incontinence, though not all are seeking adequate care or specialist consultation.
Investigative Celiac Disease Drug KAN-101 Safe, Tolerable in Phase 1 Study
Early-stage data support KAN-101, a liver-targeting drug that's vying to become the first treatment approved to treat celiac disease.
Two-Thirds of Americans with Hepatitis C Have not Cleared Disease
A cascade-of-clearance study from the CDC shows the country is far from its goal of eliminating 80% of hepatitis C cases by 2030.
6 FDA Decisions Expected Before 2024
From a novel acne cream to a breakthrough depression drug, a half-dozen agent decisions are coming through in the coming 6 months.
Microencapsulated Benzoyl Peroxide Rapidly, Significant Improves Rosacea
Analysis of a novel form of the topical drug shows rosacea is benefitted within 2 weeks of daily administration.
Ixekizumab Linked to Low Risk of Major Cardiovascular Events in Psoriatic Patients
An analysis of patients with psoriasis, PsA, or axSpA show risk of MACE with ixekizumab is consistently low.